Knocking out the dopamine reuptake transporter (DAT) does not change the baseline brain arachidonic acid signal in the mouse

International Journal of Neuroscience

Volumn 122, Issue 7, 2012, Pages 373-380

  Ramadan, Epolia ^a   Chang, Lisa ^a   Chen, Mei ^a   Ma, Kaizong ^a   Hall, F Scott ^b   Uhl, George R ^b   Rapoport, Stanley I ^a   Basselin, Mireille ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

arachidonic acid; dopamine; dopamine transporter; knockout; mouse; phospholipase A 2

Indexed keywords

ARACHIDONIC ACID; CYTOSOLIC PHOSPHOLIPASE A2; DOPAMINE 2 RECEPTOR; DOPAMINE REUPTAKE TRANSPORTER; DOPAMINE TRANSPORTER; FATTY ACID; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BODY WEIGHT; BRAIN REGION; CONCENTRATION (PARAMETERS); ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; PLASMA; QUANTITATIVE ANALYSIS; SYNAPTIC MEMBRANE;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACID; AUTORADIOGRAPHY; BODY WEIGHT; BRAIN; BRAIN MAPPING; CARBON ISOTOPES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOWN-REGULATION; FATTY ACIDS; MALE; MICE; MICE, KNOCKOUT; PHOSPHOLIPASES A2; POTASSIUM; SIGNAL TRANSDUCTION;

EID: 84862212559     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.665972     Document Type: Article

References (56)

1. Vial D, Piomelli D. Dopamine D2 receptors potentiate arachi-donate release via activation of cytosolic, arachidonic-specific phospholipase A2. J Neurochem. 1995;64:2765-72.
2. Ong WY, Sandhya TL, Horrocks LA, Farooqui AA. Distribution of cytoplasmic phospholipase A2 in the normal rat brain. J Hirnforsch. 1999;39:391-400.
3. Rapoport SI. Arachidonic acid and the brain. J Nutr. 2008;138:2515-20.
4. Robinson PJ, Noronha J, Degeorge JJ, Freed LM, Nariai T, Rapoport SI. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: Review and critical analysis. Brain Res Brain Res Rev. 1992;17:187-214.
5. Demar JC Jr, Ma K, Chang L, Bell JM, Rapoport SI. alpha-Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J Neurochem. 2005;94:1063-76. (Pubitemid 41170593)
6. Contreras MA, Chang MC, Kirkby D, Bell JM, Rapoport SI. Reduced palmitate turnover in brain phospholipids of pentobarbital-anesthetized rats. Neurochem Res. 1999;24:833-41. (Pubitemid 29296258)
7. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 2000;97:6850-55. (Pubitemid 30412803)
8. 1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology (Berl). 2005;180:735-42.
9. 2 dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats. J Cereb Blood Flow Metab. 2006;26:1378-88.
10. 2-like receptors in unanesthetized rats. Psychopharmacology (Berl). 2008;197:557-66.
11. 2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology. 2005;30:1064-75.
12. Bhattacharjee AK, Chang L, Chen M, White L, Bell JM, Bazinet RP, Rapoport SI. Chronic d-amphetamine depresses an imaging marker of arachidonic acid metabolism in rat brain. Int J Neuropsychopharmacol. 2008;11:1-13.
13. Weiss F, Imperato A, Casu MA, Mascia MS, Gessa GL. Opposite effects of stress on dopamine release in the limbic system of drug-naive and chronically amphetamine-treated rats. Eur J Pharmacol. 1997;337:219-22. (Pubitemid 27507786)
14. 2 dopamine binding site density. Neurosci Lett. 1986;72:325-9.
15. Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, Yamamoto T, Lesch KP, Murphy DL, Hall FS, Uhl GR, Sora I. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology. 2004;29:1790-9. (Pubitemid 39336790)
16. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379:606-12. (Pubitemid 26052818)
17. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA. 1998;95:4029-34. (Pubitemid 28173248)
18. Perona MT, Waters S, Hall FS, Sora I, Lesch KP, Murphy DL, Caron M, Uhl GR. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: Prominent effects of dopamine transporter deletions. Behav Pharmacol. 2008;19:566-74.
19. Gainetdinov RR, Jones SR, Caron MG. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatry. 1999;46:303-11. (Pubitemid 29335911)
20. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl GR. Cocaine rewardmodels: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA. 1998;95:7699-704. (Pubitemid 28293316)
21. Basselin M, Villacreses NE, Langenbach R, Ma K, Bell JM, Rapoport SI. Resting and arecoline-stimulated brain metabolism and signaling involving arachidonic acid are altered in the cyclooxygenase-2 knockout mice. J Neurochem. 2006;96:669-79.
22. Basselin M, Fox M, Chang L, Bell JM, Greenstein D, Chen M, Murphy DL, Rapoport SI. Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice. Neuropsychopharmacology. 2009;34:1695-1709.
23. 2beta (VIA)-deficient mice. J Lipid Res. 2010;51:3166-73.
24. Basselin M, Kim HW, Chen M, Ma K, Rapoport SI, Murphy RC, Farias SE. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res. 2010;51:1049-56.
25. Basselin M, Ramadan E, Igarashi M, Chang L, Chen M, Kraft AD, Harry GJ, Rapoport SI. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. J Cereb Blood Flow Metab. 2011;31:486-93.
26. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497-509.
27. Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coodinates. San Diego: Academic Press, Inc; 1997.
28. Yang HC, Mosior M, Johnson CA, Chang L, Chen M, Kraft AD, Harry GJ, Rapoport SI. Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal Biochem. 1999;269:278-88. (Pubitemid 29201025)
29. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
30. 2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA. 1993;90:8861-5.
31. Alexander GE, Crutcher MD, Delong MR. Basal gangliathalamocortical circuits: Parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res. 1990;85:119-46.
32. YaoWD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, CyrM, Beaulieu JM, Torres GE, Grant SG, Caron MG. Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron. 2004;41:625-38. (Pubitemid 38253073)
33. 2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse. 2007;61:573-6.
34. 3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur JNeurosci. 2000;2:19-26.
35. Jones SR, Gainetdinov RR, Hu XT, Cooper DC, Wightman RM, White FJ, Caron MG. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci. 1999;2:649-55. (Pubitemid 30491216)
36. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 1999;283:397-401.
37. 2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease. J Pharmacol Exp. Ther 2001;296:1074-84.
38. Bhattacharjee AK, Meister LM, Chang L, Bazinet RP, White L, Rapoport SI. In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease. Neuroimage. 2007;37: 1112-21. (Pubitemid 47385277)
39. 2activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl). 2007;190:103-115.
40. Parikh V, Apparsundaram S, Kozak R, Richards JB, Sarter M. Reduced expression and capacity of the striatal high-affinity choline transporter in hyperdopaminergic mice. Neuroscience. 2006;141:379-89.
41. Morice E, Billard JM, Denis C, Mathieu F, Betancur C, Epelbaum J, Giros B,Nosten-BertrandM. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology. 2007;32:2108-16. (Pubitemid 47417702)
42. Hall FS, Li XF, Sora I, Xu F, CaronM, Lesch KP,MurphyDL, Uhl GR. Cocaine mechanisms: Enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience. 2002;115:153-61. (Pubitemid 35232697)
43. Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology. 2004;29:221-8. (Pubitemid 38175141)
44. Rossetti ZL, Hmaidan Y, Gessa GL. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol. 1992;221:227-34.
45. Paulson PE, Robinson TE. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: A microdialysis study in behaving rats. Synapse. 1995;19:56-65.
46. 3 dopaminergic sites in human, rat, and calf brain. J Neurochem. 1982;39:1363-73.
47. Seeman P, Schaus JM. Dopamine receptors labelled by [3H]quinpirole. Eur J Pharmacol. 1991;203:105-9.
48. 2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse. 2002;46:235-9.
49. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci. 1998;18:1979-86. (Pubitemid 28141404)
50. Hesse S, Ballaschke O, Barthel H, Sabri O. Dopamine transporter imaging in adult patients with attentiondeficit/hyperactivity disorder. Psychiatry Res. 2009;171:120-8.
51. 123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology. 2007;55:156-62.
52. Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods. 2004;140:169-81. (Pubitemid 39625865)
53. Sora I, Li B, Igari M, Hall FS, Ikeda K. Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Ann N Y Acad Sci. 2010;1187:218-46.
54. 2C receptors in serotonin transporter knockout mice. JNeurochem. 2003;84:1256-65.
55. 2 activation in awake rat in response to 5-HT2A/2C agonist, (+-)-2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology. 2003;28:244-252.
56. Giovacchini G, Lerner A, ToczekMT, Fraser C, Ma K, DeMar JC, Herscovitch P, Eckelman WC, Rapoport SI, Carson RE. Brain incorporation of [11C]arachidonic acid, blood volume, and blood flow in healthy aging: A study with partial-volume correction. J Nucl Med. 2004;45:1471-9. (Pubitemid 47618500)